Chemo, Immunotherapy Feasible in Metastatic Bladder Cancer
WEDNESDAY, April 11, 2018 -- Gemcitabine and cisplatin (GC) plus ipilimumab is associated with a 69 percent objective response rate and 61 percent one-year overall survival for patients with metastatic urothelial cancer, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Immunotherapy | Pharmaceuticals | Study | Yervoy